乙酰化
泛素连接酶
癌症研究
泛素
赖氨酸
锡尔图因
乙酰转移酶
P300-CBP转录因子
生物
细胞生物学
西妥因1
下调和上调
组蛋白脱乙酰基酶
表观遗传学
细胞生长
化学
组蛋白
组蛋白乙酰转移酶
翻译后调节
HDAC4型
细胞周期
细胞周期检查点
磷酸化
基因表达调控
细胞
癌变
作者
Jian Yang,Zhike Chen,Weiguo Hu,Weibiao Zeng,Zhe Lei,Xin Tong,Qifan Li,Gaomeng Luo,Kang Hu,Zhimeng Chen,Zeyi Liu,Chang Li,Chun Xu,Cheng Ding,Hongtao Zhang,Jun Zhao
标识
DOI:10.1038/s41419-025-08034-9
摘要
Tripartite motif containing 25 (TRIM25), an E3 ubiquitin ligase that plays an important role in bioprocesses, is frequently elevated in malignant tumors. However, it remains unclear how TRIM25 protein expression is regulated in non-small cell lung cancer (NSCLC). Here, we find that TRIM25 is hyper-expressed in NSCLC tissues and associated with poor prognosis of NSCLC patients. Both in vitro and in vivo experiments indicate that TRIM25 facilitates tumor proliferation and metastasis. Mechanistically, acetylation is identified as a critical post-translational modification (PTM) regulating TRIM25 protein stability in NSCLC. The lysine acetyltransferase cAMP-responsive element-binding (CREB)-binding protein (CBP) mediates acetylation of TRIM25 at lysine 392, which is counteracted by the deacetylase Sirtuin 7 (SIRT7). Notably, the acetylation of TRIM25 enhances its interaction with ubiquitin specific peptidase 7 (USP7), resulting in reduced ubiquitination of TRIM25. In summary, our study reveals a novel acetylation modification site, thus providing new insights into an epigenetic regulation of TRIM25 in human cancer, and suggesting that pharmacological inhibition of TRIM25 acetylation is a potential anti-tumor strategy.
科研通智能强力驱动
Strongly Powered by AbleSci AI